Pharmacokinetics of Nifedipine‐Sustained Release Tablets in Healthy Subjects After a Single Oral Administration: Bioequivalence Analysis and Food Effects
Clinical Pharmacology in Drug Development · 2023
DOI: 10.1002/cpdd.1269 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2023. Verfasst von You-Xuan Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Clinical Trial Center, Xiangya Hospital, Central South University, Changsha, PR China. Hauptthemen laut MEDLINE: Nifedipine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
We compared newly developed delayed‐release oral tablets (test) of 30‐mg nifedipine (NFP) with its marketed counterpart (30 mg; reference) in healthy adult Chinese volunteers to assess the former's bioequivalence. This was a randomized, open‐label, four‐period, crossover trial study including fasting and fed trials. The participants were randomly administered test or reference formulations (1:1 ratio) throughout each period, with a 7‐day washout period. In the next session, they were administered the alternate products. Liquid chromatography–tandem mass spectrometry and WinNonlin software were used to evaluate the bioequivalence of the maximum plasma concentration (C max ) of NFP and the area under the concentration–time curve (AUC). In total, 46 and 48 people participated in the fasting and postprandial trials. In both groups, the 90% confidence intervals of geometric mean ratios of C max , AUC from time zero to time t, and AUC from time zero to infinity were in the equivalence range (80%–125%). When NFP was administered concomitantly with a high‐fat meal, time to maximum concentration was approximately twofold earlier, absorption was approximately 4.8% less, and C max exhibited a slight change relative to those under fasting conditions. Moreover, no serious adverse events were recorded in the participants. The present findings confirm the bioequivalence of test and reference formulations of NFP tablets under fasting and postprandial conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Phase I Clinical Trial Center, Xiangya Hospital, Central South University, Changsha, PR China.
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, PR China.
Zitieren
APA
Wu, Y. X., Zhong, X. F., Li, X. M., Liu, W. L., Zhang, Y. X., Shen, Q. Y., Xu, S. M., & Xu, P. S. (2023). Pharmacokinetics of Nifedipine‐Sustained Release Tablets in Healthy Subjects After a Single Oral Administration: Bioequivalence Analysis and Food Effects. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1269
Vancouver
Wu YX, Zhong XF, Li XM, Liu WL, Zhang YX, Shen QY, et al. Pharmacokinetics of Nifedipine‐Sustained Release Tablets in Healthy Subjects After a Single Oral Administration: Bioequivalence Analysis and Food Effects. Clinical Pharmacology in Drug Development. 2023. doi:10.1002/cpdd.1269
BibTeX
@article{Wu2023,
author = {Wu, You-Xuan and Zhong, Xue-Feng and Li, Xiao-Min and Liu, Wan-Li and Zhang, Yan-Xin and Shen, Qiu-Ying and Xu, Su-Mei and Xu, Ping-Sheng},
title = {Pharmacokinetics of Nifedipine‐Sustained Release Tablets in Healthy Subjects After a Single Oral Administration: Bioequivalence Analysis and Food Effects},
journal = {Clinical Pharmacology in Drug Development},
year = {2023},
doi = {10.1002/cpdd.1269}
}
EUVIMED